Clinical Trial Update: Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study [Phase 4]

View source ↗

Summary

A Phase 4 Vanguard study evaluates uptake and adherence to daily oral PrEP for HIV prevention among young African women, with results posted in June 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: HIV Prevention Trials Network | Conditions: HIV | Phase 4 | Status: COMPLETED | Results posted: 2025-06-12